Table 2.
Associations between oxysterols and clinical assessments in schizophrenia patients, CHR individuals, and HCs.
| HC | CHR | SCZ | ||||
|---|---|---|---|---|---|---|
| 24OHC | 27OHC | 24OHC | 27OHC | 24OHC | 27OHC | |
| Total MCCB scores | 0.210 (0.186) | 0.025 (0.327) | 0.335 (0.193) | 0.399 (−0.169) | 0.077 (−0.279) | 0.778 (0.045) |
| PANSS positive | – | – | – | – | 0.806 (−0.029) | 0.010 (−0.299) |
| PANSS negative | – | – | – | – | 0.029 (0.255) | 0.621 (0.059) |
| PANSS general | – | – | – | – | 0.053 (0.228) | 0.587 (0.065) |
| PANSS total | – | – | – | – | 0.037 (0.244) | 0.659 (−0.053) |
Data was shown as p-value (correlation coefficient).
SCZ, schizophrenia; CHR, clinically high risk; HC, healthy control; BMI, body mass index; IQ, intelligence quotient; MCCB, MATRICS consensus cognitive battery; SIPS, structured interview for prodromal symptoms; PANSS, Positive and Negative Syndrome Scale; 24OHC, 24(S)-hydroxycholesterol; 27OHC, 27-hydroxycholesterol.